Update on Xeloda – NICE recommendations make headline news

Xeloda was heralded the ‘smart pill’ for metastatic breast and colorectal cancer treatment in newspapers and broadcasts across the UK on 28 May.

The National Institute for Clinical Excellence (NICE) has backed the use of the oral replacement for intravenous 5-FU in its guidance on current ‘best practice’ to UK health professionals and the public. You can access summaries and the full reports on these recommendations in breast and colorectal cancer via Xeloda[/alink] Meanwhile, across the Atlantic……Xeloda was featured in posters and abstracts from ASCO. At Xeloda: X-pecting more for patients – a closed-door investigators’ meeting – about 800 delegates had the opportunity to hear data on:

• exciting new combinations in colorectal cancer
• Xeloda in new tumour types, and
• an expanding role for Xeloda in breast cancer.

…and back to EuropeDon’t forget to attend the debate on oral Xeloda vs intravenous 5-FU therapy at the 5th International Conference: Perspectives in Colorectal Cancer (PICC) meeting in Barcelona in June.